Mazor Robotics Ltd. (NASDAQ:MZOR)‘s stock had its “hold” rating reaffirmed by equities research analysts at Barclays PLC in a report issued on Wednesday. They currently have a $34.00 price objective on the medical instruments supplier’s stock. Barclays PLC’s target price would indicate a potential downside of 34.99% from the company’s previous close.
Several other equities research analysts have also commented on MZOR. Needham & Company LLC restated a “hold” rating on shares of Mazor Robotics in a research report on Thursday, July 6th. Zacks Investment Research lowered Mazor Robotics from a “hold” rating to a “sell” rating in a research report on Tuesday, July 18th. Finally, Ladenburg Thalmann Financial Services set a $54.00 price objective on Mazor Robotics and gave the stock a “buy” rating in a research report on Wednesday, August 30th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the stock. Mazor Robotics currently has a consensus rating of “Hold” and an average price target of $37.67.
Shares of Mazor Robotics (NASDAQ:MZOR) opened at 52.30 on Wednesday. The firm’s 50-day moving average is $47.38 and its 200-day moving average is $39.22. Mazor Robotics has a 1-year low of $20.19 and a 1-year high of $55.66. The company’s market cap is $1.26 billion.
Mazor Robotics (NASDAQ:MZOR) last released its quarterly earnings data on Tuesday, August 1st. The medical instruments supplier reported ($0.16) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.09. Mazor Robotics had a negative return on equity of 28.51% and a negative net margin of 37.66%. The business had revenue of $15.46 million for the quarter, compared to analyst estimates of $15.38 million. During the same quarter in the prior year, the firm posted ($0.09) EPS. The business’s quarterly revenue was up 86.7% compared to the same quarter last year. On average, equities analysts forecast that Mazor Robotics will post ($0.77) earnings per share for the current fiscal year.
Several large investors have recently made changes to their positions in MZOR. Quantbot Technologies LP purchased a new position in shares of Mazor Robotics during the 2nd quarter valued at approximately $135,000. JPMorgan Chase & Co. lifted its position in shares of Mazor Robotics by 398.5% during the 1st quarter. JPMorgan Chase & Co. now owns 6,979 shares of the medical instruments supplier’s stock valued at $208,000 after buying an additional 5,579 shares in the last quarter. BB&T Securities LLC purchased a new position in shares of Mazor Robotics during the 2nd quarter valued at approximately $248,000. Dimensional Fund Advisors LP lifted its position in shares of Mazor Robotics by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 8,570 shares of the medical instruments supplier’s stock valued at $296,000 after buying an additional 641 shares in the last quarter. Finally, ProVise Management Group LLC purchased a new position in shares of Mazor Robotics during the 2nd quarter valued at approximately $422,000. Hedge funds and other institutional investors own 25.92% of the company’s stock.
About Mazor Robotics
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.